Which commercial Chinese polyherbal preparations combined with ACEI/ARB is effective and safe for IgA nephropathy? A systematic review and network meta-analysis
Li Zheng, Xiaotong Gu, Lin Zhang, Chumeng Yang, Xuelin Sun, Weina Zhang, Songtao Yang · 2026
Read Which commercial Chinese polyherbal preparations combined with ACEI/ARB is effective and safe for IgA nephropathy? A systematic review and network meta-analysis by Li Zheng, Xiaotong Gu, Lin Zhang, Chumeng Yang, Xuelin Sun, Weina Zhang, Songtao Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13342400.txt.
Description
Li Zheng and colleagues published a 2026 systematic review and network meta-analysis of Chinese polyherbal products paired with standard kidney drugs for IgA nephropathy. Six commercial products were compared, each added to ACE inhibitor or ARB therapy, to rank which pairs work best and stay safe.
The team pooled 70 randomized trials with 4,855 patients, though bias risk across trials was high. Bailing capsules plus standard drugs likely raised response rates and cut urine protein, while other products helped kidney markers such as creatinine and urea nitrogen. Side effects looked similar for most pairs, with Huangkui showing more reactions. The authors rate much of the proof as low to moderate certainty.
Catalog record
| CREATOR | Li Zheng, Xiaotong Gu, Lin Zhang, Chumeng Yang, Xuelin Sun, Weina Zhang, Songtao Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46551 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |